+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Regorafenib for cancer

Regorafenib for cancer

Expert Opinion on Investigational Drugs 21(6): 879-889

Regorafenib (BAY 73-4506) is a novel, orally active, diphenylurea multikinase inhibitor of VEGFR1-3, c-KIT, TIE-2, PDGFR-β, FGFR-1, RET, RAF-1, BRAF and p38 MAP kinase. This review covers the preclinical development of regorafenib as well as the pivotal Phase I studies. The safety profile of regorafenib is discussed in context with other oral multikinase inhibitors bearing a similar target profile. Current clinical developments, especially in colorectal cancer (CRC) and gastrointestinal stromal tumor (GIST), are addressed. Open questions on clinically useful biomarkers predicting response with regard to a personalized therapy strategy are also being discussed. Regorafenib (BAY 73-4506) is a novel, orally active multikinase inhibitor that is well tolerated in preclinical mouse models as well as clinically according to Phase I - III trials performed. The toxicity profile is comparable with other oral multikinase inhibitors with similar molecular targets. Regorafenib has promising antineoplastic activity in various tumor types. Two large, randomized Phase III pivotal registration studies in patients with GIST and CRC, respectively, already completed enrolment, with final results being awaited. Further extensive clinical development as a single agent or in combination with standard chemotherapeutic agents in various malignant tumors is ongoing. Moreover, regorafenib has recently been granted Orphan Drug Status for GIST tumors and 'fast track' status for both GIST and CRC by the FDA.

(PDF emailed within 0-6 h: $19.90)

Accession: 055446601

Download citation: RISBibTeXText

PMID: 22577890

DOI: 10.1517/13543784.2012.684752

Related references

Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy. Cancer Biology & Therapy 16(12): 1710-1719, 2016

Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma. European Journal of Cancer 99: 28-36, 2018

Regorafenib in gastric cancer. Translational Gastroenterology and Hepatology 2: 16-16, 2017

Long-Term Survival of a Patient with Metastatic Liver and Para-Aortic Lymph Node Cancer from Colon Cancer Treated with Regorafenib. Gan to Kagaku Ryoho. Cancer & ChemoTherapy 44(12): 1732-1734, 2018

Regorafenib for metastatic colorectal cancer. Lancet 381(9877): 1537-1537, 2013

Regorafenib in metastatic colorectal cancer. Expert Review of Anticancer Therapy 14(3): 255-265, 2014

SHP-1 is a target of regorafenib in colorectal cancer. Oncotarget 5(15): 6243-6251, 2015

Regorafenib for metastatic colorectal cancer. Lancet 381(9877): 1537-1538, 2013

Regorafenib in the treatment of colorectal cancer. Expert Opinion on PharmacoTherapy 17(1): 137-145, 2016

Regorafenib in metastatic colorectal cancer. Clinical Advances in Hematology & Oncology 10(5): 324-325, 2015

Regorafenib Approved for Liver Cancer. Cancer Discovery 7(7): 660-660, 2017

The role of regorafenib in metastatic colorectal cancer. Lancet. Oncology 16(6): 596-597, 2015

Regorafenib: A Review in Metastatic Colorectal Cancer. Drugs: -, 2018

Regorafenib: from bench to bedside in colorectal cancer. Expert Review of Clinical Pharmacology 6(3): 243-248, 2013

Regorafenib approved in Metastatic Colorectal cancer. Bulletin du Cancer 100(10): 1027-1029, 2013